Given Imaging: A Capsule View of GI Diagnostics' Future

Despite all of the recent advances in diagnostic imaging, the small bowel remains a black box with physicians still unable to directly view the roughly 20-foot length of this portion of the gastrointestinal tract. Small bowel direct imaging is currently limited to the first few feet through a traumatic procedure called push enteroscopy. The result of the small bowel's diagnostic inaccessibility is that many patients with conditions that arise in the small intestines are forced to undergo numerous invasive tests of other parts of the GI tract, none of which may produce conclusive results. Given Imaging has taken a futuristic approach to GI imaging by utilizing advances in a number of disparate fields, including visualization, miniaturization, and chip construction, combined with principles taken from Israeli missile design technology. The company has developed an ingestible, grape-sized capsule that transmits direct images of the entire GI tract--including for the first time the small bowel--as the device travels through and eventually is expelled from the body in a procedure called capsule endoscopy. All this while the patient goes about his or her normal daily routine. Capsule endoscopy represents the first major breakthrough in gastrointestinal diagnostic imaging in nearly 25 years. Given has been on the fast track. Less than four years from its founding, the company has obtained product approvals and done a successful IPO. But its biggest challenge remains: to overcome the inertia from the lack of innovation in GI medicine and convince gastroenterologists to adopt this radical new diagnostic tool.

by Stephen Levin

What does the science fiction movie classic, "Fantastic Voyage," with its visually spectacular miniaturized journey through the human body, have...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Innovation

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

InVivo-Innovation-Free: ‘Interview’ article that includes different Composer content

 
• By 

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.

InVivo-Innovation-Free: ‘PDF/Ebook’ article that includes different Composer content

 
• By 

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.

How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.